The authors employed PTEN-null mice that had developed progressive disease, ranging from steatosis to fibrosis, to nonalcoholic steatohepatitis (NASH) and overt HCC. This evidence concerns the gene PTEN and metabolic dysfunction-associated steatohepatitis.